Trial Profile
A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2018
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Obesity; Weight gain
- Focus Therapeutic Use
- 01 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 04 Jun 2015 Planned End Date changed from 1 Feb 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 04 Jun 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.